Follows people with blood diseases in China to study treatment and outcomes
Collects records from people with blood cancers and bleeding disorders over time.
Plain-language title generated from the registry record
Registry title: National Longitudinal Cohort of Hematological Diseases
Key facts
- Where
- Tianjin, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people diagnosed with a blood disease, such as leukemia, lymphoma, multiple myeloma, hemophilia or aplastic anemia, or who had a bone marrow transplant. It collects their medical records and follows them over time.
- Sex
- All sexes can join.
- Disease stage
- Diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma or a bleeding disorder, or had a bone marrow transplant, at the investigating hospitals from January 1, 2020.
Main reasons for not taking part
- No long-term follow-up information is available for the patient, for example because of a serious other disease.
- Alcohol or drug addiction affects the ability to follow the study requirements.
- The investigator finds conditions that may endanger the patient's safety or affect compliance.
Read by machine on 12 November 2026.
Where in China
- Institute of Hematology & Blood Diseases HospitalTianjin, ChinaContact: Zhen Song, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT04645199
- Record updated
- 12 February 2026
- Original description
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China.Read full original descriptionShow less
National Longitudinal Cohort of Hematological Diseases (NICHE)
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China.
Method The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.
Inclusion: Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020.
Exclusion: Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease; Alcohol and drug addictions affect their ability to comply with study requirements; According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.